bioAffinity Technologies, Inc. Additional Paid in Capital
bioAffinity Technologies, Inc. (BIAF) had Additional Paid in Capital of $79.27 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapital · last filed 2026-08-07
- 2026-06-30: Additional Paid in Capital $79.27M.
- 2026-03-31: Additional Paid in Capital $75.81M.
- 2025-12-31: Additional Paid in Capital $75.80M.
- 2025-09-30: Additional Paid in Capital $74.29M.
| Period end | Additional Paid in Capital | Additional Paid in Capital as first filed |
|---|---|---|
| 2026-06-30 | $79.27M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $75.81M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $75.80M 10-Q · filed 2026-08-07 | |
| 2025-09-30 | $74.29M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $58.03M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $57.62M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $56.24M 10-K · filed 2026-03-16 | $56.14M 10-K · filed 2025-03-31 |
| 2024-09-30 | $53.71M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $52.03M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $51.74M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $49.39M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $49.16M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $47.98M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $47.81M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $47.65M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $47.53M 10-Q · filed 2022-11-14 | |
| 2021-12-31 | $12.70M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |